{
  "name" : "twin.sci-hub.se_6675_4bbfddbc6d8c47a05c71e239e890177f_zhang2018.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Enhanced Photodynamic Therapy by Reduced Intracellular Glutathione Levels Employing Nano-MOF with Cu (II) as Active Center",
    "authors" : [ "Wei Zhang", "Jun Lu", "Xiaonan Gao", "Ping Li", "Wen Zhang", "Yu Ma", "Hui Wang", "Bo Tang" ],
    "emails" : [ ],
    "sections" : [ {
      "heading" : null,
      "text" : "oxygen species (ROS) produced in the cell directly determines therapeutic effect. Improvement in ROS concentration can be realized by reducing the glutathione (GSH) level or increasing the photosensitizer amount. However, excessive photosensitizer may cause side effects. Therefore, the development of photosensitizers combining the ability of reducing GSH levels through synergistically improving ROS concentration to strengthen the efficacy of PDT for tumor is important. We report a nano-metal-organic framework (Cu (II)-metalated nano-MOF {CuL-[AlOH]2}n (MOF-2, H6L = mesotetrakis(4-carboxylphenyl)porphyrin)) based on Cu (II) as active center for PDT. This MOF-2 is readily uptaken by breast cancer cells, and high-level ROS is generated under light irradiation. Meanwhile, intracellular GSH is considerably decreased owing to absorption on MOF-2, synergistically increasing ROS concentration and accelerating apoptosis, thereby enhancing the effect of PDT. Notably, based on direct adsorption of GSH, MOF-2 showed comparable effect with commercial antitumor drug camptothecin in mouse breast cancer treatment. This work provides strong evidence for MOF-2 as a promising new PDT candidate and anti-cancer drug.\nPhotodynamic therapy (PDT) plays an important role in cancer therapy as treatment for skin cancer and subcutaneous tumor tissue. [1] The main principle of PDT is to produce a large number of ROS by using photosensitizers under light irradiation and thus utilize the toxicity of reactive oxygen species (ROS) to kill cancer cells, achieving the treatment of tumor. [2] For improving therapeutic effect, numerous studies focused on producing more ROS by using different kinds of photosensitizer. [3] However, the ROS generated from the photosensitizer could be reduced by a high concentration of glutathione (GSH) in cells, which decreases the effect of PDT. [4] Moreover, excessive amounts of the photosensitizer may cause side effects. Thus, to develop the solution with moderate photosensitizers combining concurrently reduced GSH levels, which can synergistically raise ROS levels to strengthen the efficacy of PDT is highly significant. However, to date, few works have been reported on the direct reduction of intracellular GSH in PDT. At present, Stone group used the cysteine enzyme to eliminate the levels of cysteine as raw material for GSH, thereby decreased the GSH level, increasing ROS levels, and inhibited tumor growth. [5] Zhang and Tan group developed a photosensitizer chlorine6/MnO2 nanosystem, which decreasing the level of GSH by MnO2. [6] Qu’s group used g-C3N4 nanosheets, enhancing light-triggered ROS generation and the depletion of intracellular GSH levels. [7] Therefore, the design of a new bifunctional material that integrates the production of ROS and simultaneous elimination of intracellular GSH is of great importance.\nAs a new type of porous complex, metal–organic frameworks (MOF) have been widely used in biosensing, catalysis, and PDT owing to the advantages of structural diversity and high specific surface area. [8] In particular, MOF can improve the ROS level as photosensitizers. For example, the Liu group synthesized a new MOF based on Hf 4+ and a porphyrin derivative, which produced\nROS and improved the PDT effect. [9] Ju’s group combined the photosensitizer Ce6 and MOF, with the photosensitizer Ce6 used to produce ROS applied for PDT of cancer. [10] The abovementioned works merely employed the MOF or MOF combined other photosensitizer to generate ROS for tumor treatment. Considering active center and large specific surface area of the MOF, we supposed that a rationally designed nano-MOF with dual function is should be qualified to directly reduce GSH levels and synchronously serve as PDT photosensitizer, which should intensify treatment efficacy. Moreover, the above-mentioned MOF may reduce photosensitizer dose, avoiding side effects of PDT treatment.\nScheme 1. Schematic of the mechanism of the nano-MOF for enhanced PDT.\nThe nano-MOF can adsorb GSH efficiently and decrease the level of GSH for\nhighly efficient PDT. Schematic of nano-MOF enhanced PDT by decreased\nintracellular glutathione levels.\nTo achieve the above goal, we designed and constructed a nano-metal-organic framework (Cu (II)-metalated nano-MOF {CuL-[AlOH]2}n (MOF-2, H6L = meso-tetrakis(4carboxylphenyl)porphyrin)) for PDT. Thereinto, Cu(II) as active center of MOF-2 can specifically bind and absorb GSH, thus directly decreasing intracellular GSH concentration, increasing the ROS level. In the meantime, porphyrin ligand can be used as photosensitizer to generate abundant ROS under light irradiation. The two actions of MOF-2 will combine to substantially heighten the levels of ROS. We utilized MOF-2 in the treatment of mouse breast cancer tumors, and found it exhibited comparable therapeutic effect with commercially available anticancer drug camptothecin (CPT). Importantly, MOF-2 used in mouse breast cancer tumors synergistically increase ROS concentration, resulting in apoptosis and enhanced PDT. Altogether, the study is of universal value and practical significance for the accurate treatment of cancer.\nWe synthesized two kinds of nano-MOF, including the aluminum–copper mixed metal MOF (MOF-2) with Cu (II) as the active center, and aluminum–metal nano-MOF (MOF-1) without Cu (II) active center as a control, in order to confirm the GSHbinding role of Cu (II) in MOF. The crystal structure and morphology of nano-MOF were characterized by XRD, IR, EDS, SEM, and TEM, respectively. [11] To test if MOF-2 can effectively absorb GSH, considering GSH could scavenger ROS, we compared ROS amount induced by MOF-2 and MOF-1 in the\nA cc\nep te\nd M\nan us\ncr ip\nt\nThis article is protected by copyright. All rights reserved."
    }, {
      "heading" : "COMMUNICATION",
      "text" : "absence or presence of GSH. ROS levels were measured using a commercial fluorescent probe DCFH (2,7-dichlorofluorescein) [7]\n(Figure 1b). When 1.0 mM GSH was added, the fluorescence intensity decreased in the solutions of MOF-1 and MOF-2, meaning the decrease of ROS concentration resulted from the interaction between ROS and GSH. Apparently, fluorescence in MOF-2 solution was about 2-time stronger than MOF-1, which indicated higher concentration of ROS generated by MOF-2. The results indicated that the binding between GSH and Cu (II) of MOF-2 maybe reduce GSH level. Then, we analyzed the amount of GSH remaining in the supernatant after centrifugation to remove MOF, using a GSH fluorescence kit. As can be seen from the illustration in Figure 2b, in the presence of GSH, the amount of ROS in MOF-2 material was more than that of MOF-1, which indicated that MOF-2 was adsorbed more GSH. Figure 1c showed strikingly less GSH in MOF-2 solution than MOF-1. Further experiment displayed that the concentration ratio of GSH before and after treatment with MOF-2 of 15 µM reached 8.0 (Figure 1d). These results demonstrate that Cu (II) and porous property of MOF-2 endow it excellent adsorption capacity for GSH.\nFigure 1. (a) PXRD patterns for the as-synthesized sample MOF-1 and MOF2, and PXRD patterns for the reported crystal sample; [12] (b) Influences of MOF-2 (Cu-MOF) and MOF-1 (copper-free MOF) on GSH adsorption using the ROS probe under 650 nm light irradiation, inset is the illustration of quantitative description for influences on MOF-2 and MOF-1 during GSH adsorption, F1 & F2 are the fluorescence intensities of DCFH in MOF-1 & MOF-2 respectively; (c) The concentration of GSH in the supernatant solution treated with MOF-1 and MOF-2 via a commercial kit measurement; (d) Supernatant solutions’ GSH concentration via a commercial kit measurement after the treatment of different amount of MOF-2.\nTo verify the specificity adsorption of MOF-2 to GSH, we studied the fluorescence response between MOF-2 with GSH, mercapto compounds, and sulfur-containing small molecular species. The coordination of Cu (II) with nitrogen atoms in the porphyrin structure quenched fluorescence of MOF-2. While fluorescence of porphyrin in MOF-2 restored when the GSH bound Cu (II), of which excitation was 420 nm, emission peaks\nwere 603 and 650 nm. Figure S6 showed that the fluorescence response of HS - with MOF-2 was significantly weaker than that of GSH. The Cys/GSH ratio was selected at the physiological concentration range, and we found that the fluorescence response of MOF-2 with Cys was remarkably less than that of GSH. As for other sulfur compounds of high concentrations, such as SO4 2− (1.0 mM), SO3 2− (1.0 mM), S2O3 2− (1.0 mM), and (8) SCN − (1.0 mM), although the concentration of the abovementioned sulfur compounds was markedly higher than that of GSH, whereas the fluorescence change was small. These results indicated that MOF-2 exhibited highly selective adsorption capacity for GSH. To study the interaction between MOF-2 and GSH in depth, we optimized the experimental conditions including effects of pH and concentration (Figure S7). Under optimal conditions, we investigated the ability of MOF-2 to selectively adsorb GSH by fluorescence response. We found that low concentrations of GSH could enhance the fluorescence intensity of MOF-2 in the concentration range of 0−200 µM (Figures S8 and S9), with linear relationship in the range of 0−5.0 µM and 5.0 µM−100 µM, and the correlation coefficients were 0.9915 and 0.9706, respectively. We speculated the GSH competed with nitrogen atoms in porphyrin and coordinated with Cu (II); therefore, the fluorescence of porphyrin quenched by Cu (II) was linearly restored. Conversely, at concentrations exceeding 200 µM, GSH can quench the fluorescence of MOF-2. In this case, we supposed that MOF-2 existed as a fluorescence quenching aggregation state. Based on these principles, the fluorescence response of the MOF was employed to characterize the adsorption interaction between MOF and GSH in live cell.\nFigure 2. Dynamic light scattering image of (a) MOF-2 (5.0 µM); (b) MOF-2 (5.0 µM) and GSH (30.0 µM); (c) MOF-2 (5.0 µM) and GSH (3.0 mM); (d) MOF-2 (5.0 µM) and GSH (3.0 mM), followed by an addition of Cu (II) (100 µM).\nNext, mechanism of fluorescence change caused by adsorption was further explored. We used dynamic scattering to examine the hydration radius of MOF-2 in the presence of different concentration GSH. Figure 2b showed that there was\n10.1002/ange.201710800\nA cc\nep te\nd M\nan us\ncr ip\nt\nAngewandte Chemie\nThis article is protected by copyright. All rights reserved."
    }, {
      "heading" : "COMMUNICATION",
      "text" : "no significant change in the hydration radius of MOF-2 with 30.0 µM GSH, indicating no gathering of MOF-2 occurred. After addition of 3.0 mM GSH, the hydrated particle size of the material evidently increased (Figure 2c), indicating that a large amount of GSH resulted in the aggregation of MOF-2. Aggregation leads to fluorescence quenching of MOF-2. To further confirm this hypothesis, 100 µM Cu (II) was added. The result in Figure 2d showed that hydration radius of MOF-2 reduced obviously, which suggested MOF-2 dispersed again. All together, these results demonstrated that the MOF-2 adsorbed on GSH was present in a dispersed luminescent form under low concentration GSH. On the contrary, in the case of high GSH concentration, MOF-2 was existed as aggregated state of fluorescence quenching with increasing amount of adsorbed GSH.\nThe adsorption of MOF-2 to the intracellular GSH was studied, which was reflected via changes on fluorescence properties of MOF-2. Due to low concentration the GSH enhances its fluorescence, and high concentration quenches fluorescence. We found that HepG2 cells incubated with MOF-2 showed weak fluorescence (Figure S10a). This should be ascribed to high concentration of GSH in cancer cells that was directly adsorbed by MOF, which quenches fluorescence of MOF-2. To verify if the fluorescence change was induced by GSH, GSH scavenging reagent N-Ethylmaleimide (NEM) was used to treat cells (Figure S10b). Brighter fluorescence was observed in these cells, meaning dispersed form of MOF-2 due to significant decrease of GSH level. These results confirmed that MOF can specifically absorb GSH in live cells.\nFigure 3. (a) Cell viability of LX-2 cells (green) and HepG2 cells (yellow). (b) Ratio of cell viability at different concentrations of MOF-2, the ratio = LX-2 cells/ HepG2 cells.\nTo further confirm the binding of MOF-2 to different concentrations of GSH in cells, MOF-2 was used to observe fluorescence changes in buthionine sulf oximine (BSO) induced HepG2 cells (Figure S11). In the first 30 min of apoptosis, the high concentration of GSH quenches the fluorescence of MOF-2; after 30 min, the concentration of GSH decreased during apoptosis, and the cell fluorescence brightness gradually increased with time. Generally speaking, with increasing degree of apoptosis, intracellular GSH concentration decreased, cell fluorescence imaging brightness gradually increased (Figure S11). These results confirmed that MOF-2 can adsorb different concentrations of GSH in cells. Moreover, the concentration of GSH can be indicated by fluorescence imaging.\nNext, we examined the influences of MOF-2 on the survival rate of normal cells and cancer cells through the MTT\nexperiment. Figure 3 showed the activity of cancer cells HepG2 and normal cells LX-2 gradually decreased with increasing concentration of MOF-2. The relative cell viability of normal cells LX-2 / HepG2 cells was 2.0 when the concentration of MOF-2 was 120 µM (Figure 3b), which demonstrated that the MOF-2 showed potential as a new type of anticancer drug through regulating the level of GSH in cancer cells. Notably, at the same MOF-2 concentration, the cell viability of HepG2 cells was significantly lower than that of normal cells possibly because the amount of GSH required for cancer cells was significantly higher than that of the normal cell. Thus, the influence of the same amount of MOF-2 on cell viability was that the cancer cells were larger than normal cells.\nFigure 4. (a) Cell viability of 100 µM MOF-2 stained with PBS, MOF-2, camptothecin (CPT), MOF-2 and CPT in combination for 24 h; (b) Cell viability of MOF-2 stained with PBS, MOF-2, BSO, MOF-2 and BSO in combination for 24 h. Experimental details: MOF-2, 100 µM; BSO 0.5 mM; CPT, 15 µM.\nWe further evaluated the effectiveness of MOF-2 to kill tumor cells by comparing with other anticancer drugs. The influence of MOF-2, CPT, BSO, MOF-2 and CPT in combination (MOF2/CPT), MOF-2 and BSO in combination (MOF-2/BSO) on viability of HepG2 cells was studied by MTT assay (Figure 4). The results showed that MOF-2, CPT, and BSO could decrease the survival rate of cancer cells. While the effect of MOF-2 on cell viability was significantly higher than those of CPT and BSO, indicating that MOF directly adsorbed GSH, reducing GSH levels and exhibiting good killing ability toward cells. When MOF-2/CPT and MOF-2/BSO were used in combination (Figures 4a and 4b), lower survival rate of cancer cells was observed, indicating that MOF-2 enhanced the killing ability of CPT and BSO to cells by GSH adsorption.\nThe MOF killing of tumor cells was further performed by flow cytometry. The effects of MOF-2, CPT, BSO, and MOF-2/CPT and MOF-2/BSO on the HepG2 were studied and morphological changes of HepG2 cells were shown in Figure S13. The green fluorescence imaging was fluorescence imaging of cell membrane stained by FITC. Notably, imaging brightness was closely related to the early stages of apoptosis. Improved cell morphological imaging was observed compared with that of the control group, indicating that MOF-2, CPT, and BSO induce cells to the prophase of apoptosis. Green fluorescence brightness increased significantly after the use of MOF-2/CPT and MOF2/BSO, respectively, indicating that the degree of apoptosis increased and the number of cells in the early stage of apoptosis increased significantly. The orange fluorescent imaging was stained by propidium iodide. The imaging brightness was closely\n10.1002/ange.201710800\nA cc\nep te\nd M\nan us\ncr ip\nt\nAngewandte Chemie\nThis article is protected by copyright. All rights reserved."
    }, {
      "heading" : "COMMUNICATION",
      "text" : "related to the late stage of apoptosis and necrosis. Compared with the control group, cell imaging showed evident brightness, indicating that MOF, CPT, and BSO on the cell killing ability increased during late apoptosis. After treatment with MOF2/CPT and MOF-2/BSO, we found that the orange fluorescent brightness was significantly enhanced, indicating that late apoptotic cells increased significantly, and the process of cell death was exacerbated. Figure 5 showed the flow cytometry analysis of apoptosis cells following treatment with different reagents. After incubation with HepG2 cancer cells, the survival rates of MOF, CPT, and BSO were 60.44%, 75.22%, and 83.13%, respectively (Figure 5); when MOF-2 and chemotherapeutic drugs were used in combination, we found survival rates of MOF-2/CPT and MOF-2/BSO of 40.57% and 17.53%, respectively, which showed that the ability to kill cells was significantly improved after MOF-2 combined with drugs. By comparison, we found that the MOF-2 exhibits potential as novel anticancer drug by directly reducing GSH levels.\nFigure 5. Flow cytometry analysis of HepG2 cells apoptosis following treatment with different reagents. (a) control; (b) 100 µM MOF-2; (c) 15 µM CPT; (d) MOF-2 and CPT in combination; (e) 0.5 mM BSO; (f) MOF-2 and BSO in combination; Experimental details: MOF-2, 100 µM; BSO, 0.5 mM; CPT, 15 µM.\nTo investigate a good therapeutic effect can be achieved by generating intracellular ROS while reducing GSH. We first measured the production of ROS in vitro using ROS probe DCFH-DA (Figure S14). We found that the ROS concentration after light irradiation was three times higher than that of without light irradiation. Appreciable increase on the amount of ROS substantiates good photosensitive properties of MOF-2. Then, produced ROS in cells was measured using ROS probe DCFHDA (Figure S15), and the fluorescence brightness was significantly stronger than that under non-irradiation (Figure S15d). The corresponding data output showed an intracellular ROS concentration ratio before and after illumination of 1:1.4 (Figure S15e), indicating that intracellular ROS level increased under light irradiation. To further evaluate ROS-producing capability of MOF-2, we measured the amount of ROS in HepG2 cells incubated with MOF-1 and MOF-2 using DCFH-DA (Figure S16). By comparison, the ability to generate ROS of MOF-2 was significantly stronger than that of MOF-1, suggesting that MOF-2 raises the ROS levels through synergies. MTT assay showed\nthat cell death rate caused by MOF-2 was obviously higher than that of MOF-1 (Figure S17), further revealing that excellent therapeutic effect of MOF-2 was achieved by generating intracellular ROS while reducing GSH. In general, the abovementioned results provided strong evidence that MOF-2 exhibited outstanding photosensitive properties, which can be selected as a powerful PDT photosensitizer.\nTo validate the efficacy of MOF enhanced PDT on tumors, we established a mouse breast tumor model (when mouse tumors grow to about 150 mm 3 , we randomly divided the tumors into eight groups, which were subjected to different treatments, and measured the weight and tumor size every 2 days). The therapy efficacy of MOF, CPT, MOF/CPT were investigated by measuring breast tumor size (a) and body weight (b). As shown in Figure 6b, the weight of the mice was less affected after 14 days of treatment. Figure 6a showed the influence of MOF, CPT, MOF/CPT, and 650 nm laser irradiation conditions on the tumor size. As time went on, the size of the tumor gradually increased. Compared with control, the production of tumor was inhibited obviously after using MOF-2. The MOF-2 and the anti-cancer drug CPT all can inhibit tumor growth. When MOF-2 was combined with CPT, the treatment effect was markedly improved. Notably, after fourteen days of treatment, MOF-2 exhibited best performance in inhibiting tumor growth under 650 nm light irradiation (Figure 6a). This finding demonstrated the ability of MOF-2 to direct adsorption of GSH, which remarkably improved the ROS levels and significantly enhanced PDT effect. The efficacy of MOF-2 on PDT was basically identical to that of MOF2 combined with CPT. Hence, the MOF-2 exhibited ability to enhance the effect of PDT by directly absorbing intracellular GSH. To further confirm the in vivo efficacy, the therapeutic effect of the MOF-2 regarding from tumor weights was performed (Figure S19 and S20). The tumor weights after MOF2 treatment was significantly reduced than that of the control group, which well demonstrated the in vivo efficacy of the MOF2 for PDT. In addition, the data about in vivo toxicity of organs was provided (Figure S21) through test of tissue slides (heart liver, spleen, lung and kidney, respectively). MOF-2 was injected directly into the tumor section. After treatment, the MOF-2 has less effect on other organs, which indicated the MOF-2 has less in vivo toxicity.\nFigure 6. Effects of MOF (10 mg/kg), CPT (2.5 mg/kg) alone and in combination and the effect of light conditions on tumor size (a) and body weight (b). light irradiation: under 50 mW/cm 2 650 nm light irradiation 15 min every day.\nTo reduce effect of high GSH concentration on PDT, we developed nano-MOF with Cu (II) as the active center to\n10.1002/ange.201710800\nA cc\nep te\nd M\nan us\ncr ip\nt\nAngewandte Chemie\nThis article is protected by copyright. All rights reserved."
    }, {
      "heading" : "COMMUNICATION",
      "text" : "enhance the effect of PDT by the direct adsorption of GSH. Utilizing the porous structure of MOF-2 and combining the role of Cu (II), the level of GSH was reduced dramatically. Through directly interaction between MOF-2 and GSH, the effects of the MOF-2 toward cancer cells were twice than that of normal cells. Thus, the MOF-2 showed comparable therapeutic efficacy with commercial anticancer drug CPT. More importantly, the MOF-2 as photosensitizer for PDT of breast cancer can synergistically increases the levels of ROS, which enhanced the effect of PDT. The results of our study not only provide a new approach for the improvement of PDT but also provide new ideas for other tumor therapy methods by directly reducing the intracellular GSH to improve efficacy."
    }, {
      "heading" : "Acknowledgements",
      "text" : "This work was supported by 973 Program (2013CB933800) and National Natural Science Foundation of China (21390411, 21535004 and 21305080). The Primary Research Plan of Shandong Province (2017GSF18196). Natural Science Foundation of Shandong Province (ZR2015JL008).\nKeywords: metal organic frameworks • photodynamic therapy•\nglutathione • Cu (II) active center • adsorption\n[1] a) D. E. Dolmans, D. Fukumura, R. K. Jain, Nat. Rev. Cancer. 2003, 3,\n380-387; b) R. Bonnet, Rev. Contemp. Pharmacother. 1999, 10, 1-17; c) Z. Hou, Y. Zhang, K. Deng, Y. Chen, X. Li, X. Deng, Z. Cheng, H. Lian, C. Li and J. Lin, ACS Nano 2015, 9, 2584–2599; d) J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue, T. Hasan, Chem. Rev. 2010, 110, 2795-2838.\n[2] a) Y. Zhang, N. Zhang, Z. R. Tang, Y. J. Xu, ACS Nano 2012, 6, 9777-\n9789; b) J. I. Na, S. Y. Kim, J. H. Kim, S. W. Youn, C. H. Huh, K. C. Park, Lasers Surg. Med. 2011, 43, 200-205; c) K. Lei, S.Tan, W. Du, Y. Xu, S. Lin, Y. Zheng, F. Zou, Y. Xu, J. Liu, Tumor Biol. 2015, 1, 1-10; d) J. C. Ahn, Gen. Physiol. Biophys. 2013, 32, 405-413; e) J. F. Lovell, T. W. B. Liu, J. Chen, G. Zheng, Chem. Rev. 2010, 110, 2839-2857.\n[3] a) R. Liang, R. Tian, L. Ma, L. Zhang, Y. Hu, J. Wang, M. Wei, D. Yan, D.\nG. Evans, X.Duan, Adv. Funct. Mater. 2014, 24, 3144-3151; b) G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, M. M. Gottesman, Nat. Rev. Drug Discovery 2006, 5, 219-234; c) W. Cao, K.\nK. Ng, I. Corbin, Z. Zhang, L. Ding, J. Chen, G. Zheng, Bioconjugate Chem. 2009, 20, 2023-2031; d) P. Agostinis, K. Berg, K. A. Cengel, T. H. Foster, A. W. Girotti, S. O. Gollnick, S. M. Hahn, M. R. Hamblin, A. Juzeniene, D. Kessel, M. Korbelik, J. Moan, P. Mroz, D. Nowis, J.Piette, B. C. Wilson, J. Golab, Ca-Cancer J. Clin. 2011, 61, 250-281; e) R.Van Hillegersberg, W.J. Kort, J.H. Paul Wilson, Drugs 1994, 48, 510-527; f) G. Zheng, J. Chen, K. Stefflova, M. Jarvi, H. Li, B. C. Wilson, Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 8989-8994; g) F. Jiang, A. M. Robin, M. Katakowski, L. Tong, M. Espiritu, G. Singh, M. Chopp, Lasers Med. Sci. 2003, 18, 128-133; h) S. S. Lucky, K. C. Soo, Y. Zhang, Chem. Rev. 2015, 115, 1990-2042; i) Z. Yu, W. Pan, N. Li and B. Tang, Chem. Sci., 2016, 7, 4237-4244; j) Z. Yu, Q. Sun, W. Pan, N. Li and B. Tang, ACS Nano, 2015, 9, 11064-11704.\n[4] a) L. Cheng, C. Wang, L. Feng, K. Yang, Z. Liu, Chem. Rev. 2014, 114,\n10869-10939; b) C. Liang, L. Xu, G. Song, Z. Liu, Chem. Soc. Rev. 2016, 45, 6250-6269.\n[5] S. L. Cramer1, A. Saha, J. Liu, S. Tadi, S. Tiziani, W. Yan, K.Triplett, C.\nLamb, S. E. Alters, S. Rowlinson, Y. J. Zhang, M. J. Keating, P. Huang, J. DiGiovanni, G. Georgiou, E. Stone, Nat. Med. 2017, 23, 120-127.\n[6] H. Fan, G. Yan, Z. Zhao, X. Hu, W. Zhang, H. Liu, X. Fu, T. Fu, X. B.\nZhang, W. H. Tan, Angew. Chem. 2016, 128, 5567-5572.\n[7] E. Ju, K. Dong, Z. Chen, Z. Liu, C. Liu, Y. Huang, Z. Wang, F. Pu, J.\nRen, X. Qu, Angew. Chem. Int. Ed. 2016, 128, 11639-11643.\n[8] a) M. O. Keeffe, O.M. Yaghi, Chem. Rev. 2012, 112, 675-702; b) J. R. Li,\nJ. Sculley, H.C. Zhou, Chem. Rev. 2012, 112, 869-932; c) Y. Cui, Y. Yue, G. Qian, B. Chen, Chem. Rev. 2012, 112, 1126-1162; d) C. Wang, T. Zhang, W. Lin, Chem. Rev. 2012, 112, 1084-1104; e) J. Park, Q. Jiang, D. W. Feng, L. Q. Mao, H. C. Zhou, J. Am. Chem. Soc. 2016, 138, 3518-3525. f) K. D. Lu, C. B. He, W. B. Lin, J. Am. Chem. Soc. 2014, 136, 16712-16715; g) K. D. Lu, C. B. He, W. B. Lin, J. Am. Chem. Soc. 2015, 137, 7600-7603. h) M. Yoon, R. Srirambalaji, K. Kim, Chem. Rev. 2012, 112, 1196-1231; i) Y. Li, X. Zhao, H. Yin, G. Chen, S. Yang, Y.B. Dong, Chem. Commun. 2016, 52, 14113-14116.\n[9] J. Liu, Y. Yang, W. Zhu, X. Yi, Z. Dong, X. Xu, M. Chen, K.Yang, G. Lu,\nL.Jiang, Z. Liu, Biomaterials 2016, 97, 1-9.\n[10] J. Liu, L. Zhang, J. Lei, H. Shen, H. Ju, ACS Appl. Mater. Interfaces\n2017, 9, 2150-2158.\n[11] a) Y. Ma, H. Su, X. Kuang, X. Li, T. Zhang, B. Tang, Anal. Chem. 2014,\n86, 11459-11463; b) Y. Ma, X. Li, A. Li, P. Yang, C. Zhang, B. Tang, Angew. Chem. Int. Ed. 2017, 56, 13752-13756; Angew. Chem. 2017, 129, 13940-13944.\n[12] A. Fateeva, P. A. Chater, C. P. Ireland, A. A. Tahir, Y. Z. Khimyak, P. V.\nWiper, J. R. Darwent, M. J. Rosseinsky, Angew. Chem. Int. Ed. 2012, 51, 7440-7444; Angew. Chem. 2012, 124, 7558-7562.\n10.1002/ange.201710800\nA cc\nep te\nd M\nan us\ncr ip\nt\nAngewandte Chemie\nThis article is protected by copyright. All rights reserved."
    }, {
      "heading" : "COMMUNICATION",
      "text" : ""
    }, {
      "heading" : "Table of Contents",
      "text" : "Layout 2:"
    }, {
      "heading" : "COMMUNICATION",
      "text" : "Text for Table of Contents\nWei Zhang, Jun Lu, Ping Li*, Wen Zhang, Yu Ma, Hui Wang, and Bo Tang*\nPage No. – Page No.\nEnhanced Photodynamic Therapy by Reduced Intracellular Glutathione Levels Employing Nano-MOF with Cu (II) as Active Center\nHerein, we report a nano-MOF based on Cu (II) as active center for PDT. Intracellular GSH was\nmarkedly decreased owing to absorption on nano-MOF, synergistically increasing ROS concentration\nand accelerating apoptosis, which enhances PDT effect. Notably, through direct adsorption of GSH, the\nnano-MOF showed a comparable effect with commercial antitumor drug CPT in mouse breast cancer\ntreatment. This work provides strong evidence for nano-MOF as a promising new PDT candidate and\nanti-cancer drug.\n10.1002/ange.201710800\nA cc\nep te\nd M\nan us\ncr ip\nt\nAngewandte Chemie\nThis article is protected by copyright. All rights reserved."
    } ],
    "references" : [ ],
    "referenceMentions" : [ ],
    "year" : 2018,
    "abstractText" : "In photodynamic therapy (PDT), the level of reactive oxygen species (ROS) produced in the cell directly determines therapeutic effect. Improvement in ROS concentration can be realized by reducing the glutathione (GSH) level or increasing the photosensitizer amount. However, excessive photosensitizer may cause side effects. Therefore, the development of photosensitizers combining the ability of reducing GSH levels through synergistically improving ROS concentration to strengthen the efficacy of PDT for tumor is important. We report a nano-metal-organic framework (Cu (II)-metalated nano-MOF {CuL-[AlOH]2}n (MOF-2, H6L = mesotetrakis(4-carboxylphenyl)porphyrin)) based on Cu (II) as active center for PDT. This MOF-2 is readily uptaken by breast cancer cells, and high-level ROS is generated under light irradiation. Meanwhile, intracellular GSH is considerably decreased owing to absorption on MOF-2, synergistically increasing ROS concentration and accelerating apoptosis, thereby enhancing the effect of PDT. Notably, based on direct adsorption of GSH, MOF-2 showed comparable effect with commercial antitumor drug camptothecin in mouse breast cancer treatment. This work provides strong evidence for MOF-2 as a promising new PDT candidate and anti-cancer drug. Photodynamic therapy (PDT) plays an important role in cancer therapy as treatment for skin cancer and subcutaneous tumor tissue. [1] The main principle of PDT is to produce a large number of ROS by using photosensitizers under light irradiation and thus utilize the toxicity of reactive oxygen species (ROS) to kill cancer cells, achieving the treatment of tumor. [2] For improving therapeutic effect, numerous studies focused on producing more ROS by using different kinds of photosensitizer. [3] However, the ROS generated from the photosensitizer could be reduced by a high concentration of glutathione (GSH) in cells, which decreases the effect of PDT. [4] Moreover, excessive amounts of the photosensitizer may cause side effects. Thus, to develop the solution with moderate photosensitizers combining concurrently reduced GSH levels, which can synergistically raise ROS levels to strengthen the efficacy of PDT is highly significant. However, to date, few works have been reported on the direct reduction of intracellular GSH in PDT. At present, Stone group used the cysteine enzyme to eliminate the levels of cysteine as raw material for GSH, thereby decreased the GSH level, increasing ROS levels, and inhibited tumor growth. [5] Zhang and Tan group developed a photosensitizer chlorine6/MnO2 nanosystem, which decreasing the level of GSH by MnO2. [6] Qu’s group used g-C3N4 nanosheets, enhancing light-triggered ROS generation and the depletion of intracellular GSH levels. [7] Therefore, the design of a new bifunctional material that integrates the production of ROS and simultaneous elimination of intracellular GSH is of great importance. As a new type of porous complex, metal–organic frameworks (MOF) have been widely used in biosensing, catalysis, and PDT owing to the advantages of structural diversity and high specific surface area. [8] In particular, MOF can improve the ROS level as photosensitizers. For example, the Liu group synthesized a new MOF based on Hf 4+ and a porphyrin derivative, which produced ROS and improved the PDT effect. [9] Ju’s group combined the photosensitizer Ce6 and MOF, with the photosensitizer Ce6 used to produce ROS applied for PDT of cancer. [10] The abovementioned works merely employed the MOF or MOF combined other photosensitizer to generate ROS for tumor treatment. Considering active center and large specific surface area of the MOF, we supposed that a rationally designed nano-MOF with dual function is should be qualified to directly reduce GSH levels and synchronously serve as PDT photosensitizer, which should intensify treatment efficacy. Moreover, the above-mentioned MOF may reduce photosensitizer dose, avoiding side effects of PDT treatment. Scheme 1. Schematic of the mechanism of the nano-MOF for enhanced PDT. The nano-MOF can adsorb GSH efficiently and decrease the level of GSH for highly efficient PDT. Schematic of nano-MOF enhanced PDT by decreased intracellular glutathione levels. To achieve the above goal, we designed and constructed a nano-metal-organic framework (Cu (II)-metalated nano-MOF {CuL-[AlOH]2}n (MOF-2, H6L = meso-tetrakis(4carboxylphenyl)porphyrin)) for PDT. Thereinto, Cu(II) as active center of MOF-2 can specifically bind and absorb GSH, thus directly decreasing intracellular GSH concentration, increasing the ROS level. In the meantime, porphyrin ligand can be used as photosensitizer to generate abundant ROS under light irradiation. The two actions of MOF-2 will combine to substantially heighten the levels of ROS. We utilized MOF-2 in the treatment of mouse breast cancer tumors, and found it exhibited comparable therapeutic effect with commercially available anticancer drug camptothecin (CPT). Importantly, MOF-2 used in mouse breast cancer tumors synergistically increase ROS concentration, resulting in apoptosis and enhanced PDT. Altogether, the study is of universal value and practical significance for the accurate treatment of cancer. We synthesized two kinds of nano-MOF, including the aluminum–copper mixed metal MOF (MOF-2) with Cu (II) as the active center, and aluminum–metal nano-MOF (MOF-1) without Cu (II) active center as a control, in order to confirm the GSHbinding role of Cu (II) in MOF. The crystal structure and morphology of nano-MOF were characterized by XRD, IR, EDS, SEM, and TEM, respectively. [11] To test if MOF-2 can effectively absorb GSH, considering GSH could scavenger ROS, we compared ROS amount induced by MOF-2 and MOF-1 in the 10.1002/ange.201710800 A cc ep te d M an us cr ip t Angewandte Chemie This article is protected by copyright. All rights reserved.",
    "creator" : "pdftk 2.02 - www.pdftk.com"
  }
}